TREACE MEDICAL CONCEPTS, INC. (TMCI) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
TMCI currently has 64.6M outstanding shares. with limited dilution risk as only 9.38M additional shares (14.5%) are authorized for issuance. The company has minimally diluted shareholders by 4.19% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 08, 2026 |
10-Q filing | 64.6M shares outstanding |
65M | 9.4M |
| Aug 07, 2025 |
10-Q filing | 63.0M shares outstanding |
63M | 9.4M |
| May 08, 2025 |
10-Q filing | 62.7M shares outstanding |
63M | 9.4M |
| Feb 27, 2025 |
10-K filing | 62.1M shares outstanding |
62M | 9.4M |
| Nov 05, 2024 |
10-Q filing | 62.2M shares outstanding |
62M | 9.4M |
| Aug 06, 2024 |
10-Q filing | 62.1M shares outstanding |
62M | 9.4M |
| May 07, 2024 |
10-Q filing | 61.8M shares outstanding |
62M | 9.4M |
| Feb 27, 2024 |
10-K filing | 60.9M shares outstanding |
61M | 9.4M |
| Nov 09, 2023 |
10-Q filing | 61.6M shares outstanding |
62M | 9.4M |
| Aug 09, 2023 |
10-Q filing | 61.4M shares outstanding |
61M | 9.4M |
| May 09, 2023 |
10-Q filing | 58.7M shares outstanding |
59M | 9.4M |
| Mar 08, 2023 |
10-K filing | 55.3M shares outstanding |
55M | 9.4M |
| Nov 09, 2022 |
10-Q filing | 55.4M shares outstanding |
55M | 9.4M |
| Aug 10, 2022 |
10-Q filing | 55.3M shares outstanding |
55M | 9.4M |
| May 06, 2022 |
10-Q filing | 55.3M shares outstanding |
55M | 9.4M |
| Mar 04, 2022 |
10-K filing | 54.7M shares outstanding |
55M | 9.4M |
| Nov 04, 2021 |
10-Q filing | 53.2M shares outstanding |
53M | 9.4M |
| Aug 05, 2021 |
10-Q filing | 52.8M shares outstanding |
53M | 9.4M |
| May 25, 2021 |
10-Q filing | 38.1M shares outstanding |
38M | 9.4M |
| Apr 19, 2021 |
S-1/A filing: This S-1/A filing relates to an offering of common stock by the company and selling stockholders, with an option for underwriters to purchase additional shares. The company intends to use the net proceeds to expand its sales force, develop new products, and for other general corporate purposes. |
50M | 9.4M |